FUTURE OF HEALTHCARE

Spectrum Science Acquires The Seismic Collaborative, Deepening Expertise in Emerging Innovation and Health Technology

Spectrum Science | June 10, 2022

Spectrum Science

Spectrum Science, an independent, integrated marketing, communications and media agency hyper-focused on health and science, announced the acquisition of The Seismic Collaborative, an independent health and life science agency that specializes in supporting early-stage health tech and biotech companies. The Seismic acquisition establishes the Emerging Innovation Group within Spectrum, a new offering that expands the agency's capabilities to deliver at all points of a company and product lifecycle.

"We're delighted to welcome Seismic's incredible talent and expertise to the Spectrum team," says Jonathan Wilson, Owner and CEO of Spectrum. "For the past several years, we've worked to strategically diversify talent and capabilities within our agency, to keep pace with client needs in a rapidly evolving industry—including the burgeoning biotech and health tech sectors. With today's acquisition, we're now able to broaden the scope of clients we support, bringing a flexible model and approach to service both early-stage and start-up clients as well as those who are more established."

This new venture brings seasoned leaders with extensive experience and current business in emerging innovation and health technology to the Spectrum team, including Seismic CEO, Lisa Rodriguez, who will serve as the President of the Emerging Innovation Group within Spectrum and will play a lead role within the company's existing Health Tech practice.

"Becoming a part of the Spectrum organization strengthens Seismic's connection to clients who are growing, expanding and advancing innovation in the health tech and life science sectors. Now more than ever before, emerging companies require end-to-end, global capabilities to reach their hypergrowth goals—Spectrum is the perfect place to make that happen. Our new home provides a dynamic and vibrant extension of our services where we can evolve with our client partners throughout their lifecycle."

Seismic CEO Lisa Rodriguez

Also joining the Spectrum organization from Seismic are EVPs Melissa Laverty and Vikki Herrera, along with Seismic's full team of strategists, writers and earned and social media specialists.

Today's announcement builds on the recently announced acquisition of SONIC Health, the first deal of its kind for Spectrum in the company's 26-year history. Financing for both acquisitions was provided by Monroe Capital.

About The Seismic Collaborative

The Seismic Collaborative communicates the stories of the people, products and services that transform healthcare and save lives through a range of strategy, media relations, content and social media services. The Seismic Collaborative's model rejects traditional PR agency norms, focusing instead on high-touch, deeply engaged, collaborative partnerships that are structured upon the results achieved. To learn more, visit www.teamseismic.com.

About Spectrum Science

Spectrum Science is an integrated marketing, communications and media agency like no other. An independent, full-service agency with end-to-end capabilities, Spectrum's team are experts in science—focused on strategic engagements with our audiences. We leverage human-centered insights, motivating creative, innovative storytelling and technology to reach audiences where they are with the content they need and want. Spectrum offers global reach as the US partner and chair of Global Health Marketing & Communications (GHMC). 

Spotlight

According to the 2013 Rand report, just 35 percent of physicians have noted their EHRs have a positive effect on their job satisfaction.* The report also found that physician satisfaction is very closely associated with the EHR application they utilize, the more complex an EHR system is, the lower the general physician professional satisfaction.


Other News
HEALTH TECHNOLOGY

KLAS and Phreesia Partner to Deliver Patient Insights on Healthcare Technology

KLAS, Phreesia | May 30, 2022

KLAS, a healthcare research and insights firm, and Phreesia, a leader in patient intake, outreach and activation, are pleased to announce the release of a report that aims to shed light on patients’ preferences and expectations for the technology they interact with as a part of their healthcare experience. The report is the result of a survey designed to better understand patient sentiments on a range of topics, including how they like to schedule appointments, their participation in telehealth visits and their communication with their doctor. KLAS and Phreesia partnered together on this report because they share a common mission of improving healthcare and the patient experience, and they recognize that patients’ voices and preferences are not always reflected in healthcare technology. The two organizations leveraged the size and scale of Phreesia’s network—which performed more than 100 million patient check-ins in 2021—to get a firsthand perspective of patients’ priorities. "What do patients want?" asked Adam Gale, CEO of KLAS Research. "This report, based on a survey with nearly 13,000 patients, provides deep insights into how providers and vendors can help meet patient preferences." Phreesia surveyed patients across the U.S. over a two-week period in 2021, as they checked in to a doctor’s appointment using Phreesia’s automated intake platform. The quantitative survey asked 14 questions about patients’ experiences using healthcare technology. Respondents represented a wide range of demographic groups across age, education level, race and gender. The report includes many detailed, data-driven insights and recommendations to providers, including Digital access tools are very important to patients: Online appointment self-scheduling and check-in, price transparency and online bill pay are among the offerings patients desire most. Survey responses indicate that patients aged 18-34 are almost twice as likely to choose organizations that have digital access tools. There are gaps between what patients want and what is offered by vendors and provider organizations—for example, the ability to schedule and reschedule an appointment or request a prescription refill online. Patients are still interested in telehealth: Nearly half of respondents had at least one virtual visit in the past year. Of those who did not, 40% reported they are likely to receive care virtually in the future. Only 33% of respondents interact with a provider portal at least once a month, and 26% don’t use a portal at all, with the youngest patients (18-24 years old) most likely to fall into the latter category. The report recommends providers take a multi-pronged approach and offer technology alternatives for things like virtual care and patient communication to better engage those who rarely or never use a portal, in addition to encouraging increased portal adoption. “As the report describes, patients want to be more actively involved in their healthcare, especially since the start of the pandemic. We believe that patient-centered care is critical to the transformation of our healthcare system. It’s incredibly important to us to be able to use our insights to help providers better engage patients and improve their experience. We’re thrilled to partner with KLAS on this valuable work.” Phreesia CEO Chaim Indig This collaboration is a result of Phreesia and KLAS’ common interest in ensuring patients’ voices are heard and that technology reflects their needs and preferences. As part of the non-financial agreement, KLAS performed its own analysis of Phreesia’s data, created this report and maintains editorial rights. KLAS’ partnership with Phreesia is in no way an endorsement of Phreesia’s performance and has had no impact on Phreesia’s standing in KLAS ratings. About KLAS KLAS has been providing accurate, honest, and impartial insights for the healthcare IT (HIT) industry since 1996. The KLAS mission is to improve the world’s healthcare by amplifying the voice of providers and payers. The scope of our research is constantly expanding to best fit market needs as technology becomes increasingly sophisticated. KLAS finds the hard-to-get HIT data by building strong relationships with our payer and provider friends in the industry. Learn more at klasresearch.com. About Phreesia Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their healthcare and provides a modern, convenient experience, while enabling our clients to enhance clinical care and drive efficiency.

Read More

HEALTH TECHNOLOGY

Vitestro unveils autonomous blood drawing device, combining artificial intelligence, ultrasound imaging and robotics

Vitestro | May 31, 2022

Vitestro, a Dutch medical robotics company, unveiled the world's most advanced autonomous blood drawing device at the annual meeting of the Netherlands Society for Clinical Chemistry and Laboratory Medicine in Rotterdam. Vitestro's device combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion, ensuring accurate and secure blood collection. The venipuncture technology is adaptable to patients of 16 years of age onwards, comorbidities, and puncture difficulty. From 2023, Vitestro will initiate pivotal clinical studies for regulatory approval in Europe. EU-market introduction is anticipated in 2024. Healthcare shortages spark revolutionary developments Within healthcare, the clinical laboratory is the driving force. Accuracy and timeliness of laboratory tests are critically important, as they shape approximately 70% of all medical decisions made by physicians. It is unsurprising that blood collection is the most common invasive medical procedure, performed billions of times per year globally. Blood collection holds a pivotal role in clinical diagnostics yet is also burdened by the scarcity of skilled workers. By automating this labor-intensive procedure, we can transform the quality of care and create a sustainable healthcare system. Proprietary laboratory automation technology standardizes handling of the blood sample while the blood is collected. The device allows almost complete automation of the pre-analytical phase. This has the potential to reduce high blood test error rates, mainly caused by manual variability. In clinical studies, Vitestro already performed 1,500 automated blood draws in more than 1,000 patients with its prototype. Toon Overbeeke, Vitestro's Co-Founder and Chief Executive Officer said: "The mounting shortage of healthcare personnel is imminent. The pandemic has further led to loss of workforce, causing a bleak outlook for hospital output around the globe, and leading to reduced access and continuity of care. That's why revolutionary automation like our blood drawing device is inevitable to solve the industry's biggest problem." Outpatient phlebotomy care is redefined At first, Vitestro will implement the device in outpatient phlebotomy departments. Patients will have the option to choose between Vitestro's venipunture device or standard method. The device is intuitive to use, empowering patients to be self-reliant in the full blood collection procedure. In previous clinical trials, patients of all ages showed a high degree of openness, enthusiasm and willingness to adopt the innovation. A trained healthcare professional is able to supervise several devices, managing multiple patients simultaneously. The increased efficiency enables hospitals and clinical laboratories to address workforce shortage or even free up staff and deploy them where they are really needed. "We have spent nearly five years on the development of this breakthrough medical device. All relevant disciplines are represented in our dedicated, specialized team of 35 people. To prepare for production and commercialization, the team will double in size in the next two years. We have clear momentum in the market and will be the first to bring autonomous technology to European hospitals. With our technology we can help to build a more robust and resilient healthcare system." Toon Overbeeke, Vitestro's Co-Founder and Chief Executive Officer Anja Leyte, Director OVLG Laboratories, participating in clinical studies commented: "By introducing automated blood drawing, high quality as well as capacity is guaranteed in our laboratories. Vitestro's technology helps solving staffing shortages at our blood drawing department and improving sample standardization. Patients are also very enthusiastic." About Vitestro In 2017 Vitestro's founders rose to the challenge to create a better blood drawing experience. Today Vitestro is well underway to achieve its goal with a committed team of 35 highly skilled people with a track record in medical robotics, imaging software, AI, QA/RA and business development. Vitestro is based in Utrecht, the Netherlands. Vitestro is well funded by private investors and government subsidies.

Read More

MEDICAL DEVICES

GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

GeneQuantum Healthcare | May 16, 2022

GeneQuantum Healthcare Co., Ltd. a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage. They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugateboth with global intellectual property rights. "The core technologies that we have focused on since the founding of GeneQuantum, bring the company into the harvest period for exciting next generation bioconjugate drugs. The EC approval of GQ1005 and GQ1007 in Australia is an important milestone for the company. More than once, GeneQuantum's enzymatic site-specific conjugation platform and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates. GeneQuantum conjugation technologies are widely compatible to different molecular modalities with various Mechanism of Action. Committed to the core value of "breakthrough for humanity", GeneQuantum is dedicated to developing safe, effective, and affordable novel therapeutics for patients with cancer around the world." Dr. Gang Qin, founder, Chairman and Chief Executive Officer About GeneQuantum Healthcare Co., Ltd. GeneQuantum Healthcare Co., Ltd. is a global biotechnology company dedicated to the development of innovative biotherapeutics. The company is focused on the development of next generation bioconjugate therapeutics to address the unmet medical needs of patients globally. This press release contains statements relating to GeneQuantum's future business, future events or developments, and related statements may constitute forward-looking statements. Statements are based on current expectations and assumptions that are subject to risks and uncertainties, which may cause actual results to differ materially. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, follow-up clinical data and analysis; factors that may cause any delay, transfer or change; regulatory authority decision whether and when to approve drug applications; factors that may lead actual results to seriously deviate from current expectations, etc. No forward-looking statement can be guaranteed. Except as required by applicable laws, GeneQuantum assumes no obligation to update or revise any forward-looking information or statements.

Read More

FUTURE OF HEALTHCARE

The Department of Health - Abu Dhabi collaborates with a leading healthcare company to boost health technology and clinical research

The Department of Health - Abu Dhabi | June 17, 2022

The Department of Health – Abu Dhabi (DoH), the regulator of healthcare in the emirate, signed a Declaration of Collaboration with Johnson & Johnson Middle East FZ-LLC, to support Abu Dhabi's vision in developing a regional hub for clinical research and data generation. The new strategic collaboration seeks to bring innovative treatments and breakthrough solutions to the UAE and the MENA region as well as exchange knowledge across the healthcare sector. Witnessed by HE Abdulla bin Mohammed Al Hamed, Chairman of the Department of Health – Abu Dhabi (DoH), the signing ceremony happened during the BIO International Convention 2022 which took place between June 13-16 in San Diego, California, U.S. The Declaration of Collaboration between the parties was signed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH and Jamie Phares, Managing Director of Janssen GCC, one of the pharmaceutical companies of Johnson and Johnson. Headed by HE Abdulla bin Mohammed Al Hamed, Chairman of the Department of Health – Abu Dhabi (DoH), the Abu Dhabi delegation comprised of government officials is visiting the USA this month to explore prospects of joint collaboration within the framework of healthcare at large and life science in specific. Through these strategic collaborations, DoH and Johnson & Johnson Middle East FZ-LLC will explore key potential areas of interest to develop short and long-term projects in the generation of Data and Real-World Evidence (RWE). Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to establish the strength and sustainability of the healthcare sector as well as provide quality care to patients. "We are pleased with all that we have achieved during the Abu Dhabi Life Science Mission thus far. Our collaborations with leading healthcare companies echo Abu Dhabi's ongoing efforts to position itself as a leading life science destination as well as an incubator for innovation. Through our collaboration with Johnson and Johnson Middle East FZ-LLC, we aim to further improve the resilience and sustainability of the healthcare sector as well as provide quality care to patients in Abu Dhabi and worldwide." Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at the Department of Health – Abu Dhabi (DoH)

Read More

Spotlight

According to the 2013 Rand report, just 35 percent of physicians have noted their EHRs have a positive effect on their job satisfaction.* The report also found that physician satisfaction is very closely associated with the EHR application they utilize, the more complex an EHR system is, the lower the general physician professional satisfaction.

Resources